Levetiracetam (Keppra)
Phase 2Completed 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Restless Legs Syndrome
Conditions
Restless Legs Syndrome
Trial Timeline
Nov 1, 2003 → Oct 1, 2005
NCT ID
NCT00247364About Levetiracetam (Keppra)
Levetiracetam (Keppra) is a phase 2 stage product being developed by UCB for Restless Legs Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT00247364. Target conditions include Restless Legs Syndrome.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00985348 | Phase 1 | Completed |
| NCT00247364 | Phase 2 | Completed |
| NCT00631150 | Approved | Completed |
| NCT00630357 | Approved | Completed |
| NCT00630968 | Approved | Completed |
Competing Products
20 competing products in Restless Legs Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Gabapentin enacarbil | Astellas Pharma | Approved | 85 |
| ASP8825 | Astellas Pharma | Phase 3 | 77 |
| Regnite | Astellas Pharma | Pre-clinical | 23 |
| ASP8825 + Placebo | Astellas Pharma | Phase 2 | 52 |
| Placebo + Gabapentin enacarbil | Astellas Pharma | Approved | 85 |
| Apomorphine Sublingual Film + Placebo | Sumitomo Pharma | Approved | 85 |
| Suvorexant | Merck | Approved | 85 |
| Cabergoline | Pfizer | Phase 3 | 76 |
| Placebo + pregabalin + pregabalin | Pfizer | Phase 3 | 76 |
| placebo + Pregabalin + Pregabalin + Pregabalin + Pregabalin + Pregabalin | Pfizer | Phase 2 | 51 |
| pregabalin + placebo + pramipexole | Pfizer | Phase 3 | 76 |
| placebo and pregabalin + pramipexol + pramipexol + Pregabalin + pramipexol + pramipexol | Pfizer | Phase 3 | 76 |
| cabergoline + levodopa | Pfizer | Phase 3 | 76 |
| Rotigotine | UCB | Phase 3 | 74 |
| Neupro® | UCB | Pre-clinical | 20 |
| Rotigotine Nasal Spray | UCB | Phase 2 | 49 |
| Rotigotine | UCB | Phase 3 | 74 |
| Rotigotine + Placebo | UCB | Approved | 82 |
| Rotigotine | UCB | Phase 2 | 49 |
| Rotigotine | UCB | Phase 3 | 74 |